Tyrosine kinase inhibitor treatment outcome in a single center cohort of chronic myeloid leukemia patients. The role of the T315I ABL kinase domain mutation
Dima, Delia, Trifa, Adrian P., Paţiu, Mariana, Vesa, Cristian S., Frinc, Ioana C., Petrov, Ljubomir, Cucuianu, Andrei
SH2B3 (LNK) rs3184504 polymorphism is correlated with JAK2 V617F-positive myeloproliferative neoplasms
Trifa, Adrian P., Lighezan, Diana L., Jucan, Cristina, Tripon, Florin, Arbore, Dana R., Bojan, Anca, Gligor-Popa, Ștefana, Pop, Raluca M., Dima, Delia, Bănescu, Claudia